Key result
Post-2013 PH diagnosis linked to improved survival and ~65% 5-year survival in Group 1.
Why the study?
Advances in diagnosis and treatment have improved the course of pulmonary hypertension, prompting an evaluation of temporal changes in diagnostic hemodynamics, survival, and prognostic factors.
Does the diagnostic hemodynamic profile and survival of patients with pulmonary hypertension improve over time?
Cohort (n=257)
No
Does the diagnostic hemodynamic profile and survival of patients with pulmonary hypertension improve over time?
Advancements in the diagnosis and treatment of pulmonary hypertension have led to diagnosis with a milder hemodynamic profile and improved survival over the last 15 years.
Advances in the diagnosis and treatment of pulmonary hypertension (PH) have gradually improved the disease course. This retrospective cohort study aims to explore the diagnostic hemodynamic profile and survival of PH patients and their temporal changes, as well as investigate potential prognostic factors. Overall, 257 adult patients were diagnosed with PH following right heart catheterization (RHC) from January 2008 to June 2023 according to the hemodynamic cut-off values proposed by the corresponding ESC/ERS guidelines at the time RHC was performed. Of these patients, 46.3% were Group 1, 17.8% Group 2, 14.0% Group 3, 18.0% Group 4, and 3.0% Group 5 PH. Temporal improvement in both diagnostic hemodynamic profile and survival of patients with PH and pulmonary arterial hypertension (PAH) was identified after 2013. Survival analysis demonstrated 5-year survival rates of 65% in Group 1 PH (90.3% in idiopathic PAH) and 77% in Group 4 PH. PAH patients being at low risk at diagnosis presented a similar 1-year all-cause mortality rate (12.4%) with high-risk ones (12.8%), primarily due to non-PH-related causes of death (62%), while high-risk patients died mostly due to PH (67%). The observed improvements in diagnostic hemodynamic profiles and overall survival highlight the importance of timely diagnosis and successful treatment strategies in PH.
No takes yet. Share an insight, caveat, or question.
Papadopoulos et al. (2023) conducted a cohort in Pulmonary Hypertension (n=257). Time of diagnosis (2008-2023) was evaluated on Diagnostic hemodynamic profile and all-cause mortality (survival). Temporal improvements in diagnostic hemodynamics and overall survival were observed in patients with pulmonary hypertension after 2013, with a 65% 5-year survival rate in Group 1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: